Compare iShares Silver Trust (SLV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Smith & Nephew plc — how do they compare? iShares Silver Trust trades at $54.48 (market cap $29.02B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: iShares Silver Trust is far larger — about 2.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 89 Days and Smith & Nephew plc for 120 Days on average.
| SLV | SNN | |
|---|---|---|
Market Cap | $29.02B | $11.10B |
Volume | 16,510,334 | 1,051,703 |
52-Week High | $105.57 | $37.17 |
52-Week Low | $42.40 | $26.42 |
Typical Hold Time | 89 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV (iShares Silver Trust) is trading at $53.82, down 2.94% with a bearish technical outlook. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024. Technical indicators show strong bearish momentum with 13 sell signals from moving averages, though RSI suggests potential oversold conditions. Recent news highlights silver's volatility amid Fed policy uncertainty and Treasury yield fluctuations.
Outlook remains cautious as silver faces pressure from rising rates and dollar strength. The ETF's structure provides pure silver exposure but carries metal price volatility risks. Near-term direction depends on Fed policy clarity and industrial demand trends, with technical support at $53-54 levels offering potential entry points for long-term investors.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
